News
$21-34 Billion in US Healthcare Costs Due to Antibiotic Resistant Bacteria.

— Infectious Disease Society of America (IDSA)

January 04, 2018

Malvern, PA, January 4, 2018 — VenatoRx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that...

January 03, 2018

Malvern, PA, January 3, 2018 — VenatoRx Pharmaceuticals, a private clinical-stage pharmaceutical company, announced today that the FDA has granted the company's lead antibiotic program,...

July 27, 2017

Malvern, PA, July 27, 2017 — VenatoRx Pharmaceuticals, a private company dedicated to the discovery and development of novel therapies for highly drug resistant bacterial infections, announced that...

July 25, 2017

Malvern, PA, July 25, 2017 — VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, today announced that it has raised $42 million in a Series B...

September 12, 2016

Malvern, PA, September 12, 2016 — VenatoRx Pharmaceuticals today announced the appointment of Dr. Michael Diem to the VenatoRx Board of Directors. Dr. Diem is Senior Vice President, Business and...

July 14, 2015

St. Louis, MO, July 14, 2015 — BacterioScan Inc. announced a collaboration with VenatoRx Pharmaceuticals Inc., Malvern, PA, to help reduce the cost and time associated with antimicrobial drug...

January 01, 2015

Malvern, PA, January 1, 2015 — Dr. Tim Henkel has joined VenatoRx Pharmaceuticals as Chief Medical Officer. Dr. Henkel has spent 20 years in the biopharmaceutical industry developing...

November 13, 2014

Malvern, PA, November 13, 2014 — Jim Murphy has joined VenatoRx as Chief Financial Officer.  Jim has over 25 years’ experience as a senior financial executive in public and privately held...

Archive: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010